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Abstract
Summary We tested whether cortical porosity of the proximal
femur measured using StrAx1.0 software provides additional
information to areal bone mineral density (aBMD) or Fracture
Risk Assessment Tool (FRAX) in differentiating women with
and without fracture. Porosity was associated with fracture
independent of aBMD and FRAX and identified additional
women with fractures than by osteoporosis or FRAX
thresholds.
Introduction Neither aBMD nor the FRAX captures cortical
porosity, a major determinant of bone strength. We therefore
tested whether combining porosity with aBMD or FRAX im-
proves identification of women with fractures.
Methods We quantified femoral neck (FN) aBMD using dual-
energy X-ray absorptiometry, FRAX score, and femoral
subtrochanteric cortical porosity using StrAx1.0 software in
211 postmenopausal women aged 54–94 years with
nonvertebral fractures and 232 controls in Tromsø, Norway.
Odds ratios (ORs) were calculated using logistic regression
analysis.
Results Women with fractures had lower FN aBMD, higher
FRAX score, and higher cortical porosity than controls (all
p<0.001). Each standard deviation higher porosity was asso-
ciated with fracture independent of FN aBMD (OR 1.39; 95%
confidence interval 1.11–1.74) and FRAX score (OR 1.58;
1.27–1.97) in all women combined. Porosity was also associ-
ated with fracture independent of FRAX score in subgroups
with normal FN aBMD (OR 1.88; 1.21–2.94), osteopenia (OR
1.40; 1.06–1.85), but not significantly in those with osteopo-
rosis (OR 1.48; 0.68–3.23). Of the 211 fracture cases, only 18
women (9 %) were identified using FN aBMD T-score<−2.5,
45 women (21 %) using FRAX threshold >20 %, whereas
porosity >80th percentile identified 61 women (29 %).
Porosity identified 26% additional women with fractures than
identified by the osteoporosis threshold and 21 % additional
women with fractures than by this FRAX threshold.
Conclusions Cortical porosity is a risk factor for fracture in-
dependent of aBMD and FRAX and improves identification
of women with fracture.
Keywords Bonemineral density . Cortical porosity . FRAX .
Nonvertebral fractures
Introduction
Bone fragility is a public health problem due to the accompa-
nying increased morbidity, mortality, and financial costs
resulting from fractures, in particular, nonvertebral and hip
fractures [1, 2]. To reduce the burden of disease cost-
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effectively, methods are needed to identify persons at risk for
fracture in need of treatment and persons at low risk to avoid
unnecessary treatment. The most common approach used to
assess fracture risk is measurement of femoral neck (FN) areal
bone mineral density (aBMD) using dual-energy X-ray ab-
sorptiometry (DXA) [3]. Although a lower aBMD is associ-
ated with higher fracture rates, most fractures occur in women
without osteoporosis as defined by the diagnostic threshold of
an FN aBMD T-score of 2.5 or more standard deviations (SD)
below the young normal mean [4, 5].
To address this lack of sensitivity, the World Health
Organization (WHO) developed the Fracture Risk
Assessment Tool (FRAX) which calculates the 10-year
probability of a major osteoporotic fracture based on a
combination of clinical risk factors and FN aBMD. This tool
has improved the identification of persons at risk of fracture in
some, but not all, cohorts [6–8]. Both aBMD and FRAX iden-
tify persons at risk, but they do not take into account the
cortical porosity, which is an important determinant of bone
strength [9, 10].
Although both cortical and trabecular bone contribute to
bone strength, 80 % of the skeleton is cortical, 70 % of all
appendicular bone loss is cortical, and 80 % of fractures in
women over 65 years of age are nonvertebral [11, 12]. Cortical
bone loss is the result of unbalanced and accelerated
intracortical remodeling initiated at points upon the
intracortical surface formed by the many Haversian canals
traversing it. As more bone is resorbed than replaced at each
remodeling site, focal enlargement of the canals occurs, adja-
cent canals coalesce forming giant pores when viewed in cross
section [13–15]. Just as the increase in porosity increases bone
fragility, several studies now demonstrate that treatment re-
duces porosity [16, 17]. Women with hip fracture have thinner
and more porous cortices than controls, and they have giant
pores [13–15]. Thus, as cortical bone is an important determi-
nant of bone strength [9], its deterioration should be quantified
in assessing fracture risk.
Studies using high-resolution peripheral quantitative com-
puted tomography (HR-pQCT) images of the distal radius and
tibia and digital X-ray radiogrammetry of metacarpal bone
have demonstrated associations between cortical porosity
and fracture [18–20]. As HR-pQCT is not widely available,
we examined whether cortical porosity quantified in vivo
using standard CT technology, which is available in most
institutions, can be used to acquire images of the cortex and
its porosity. We tested the following hypotheses: (i) measure-
ment of cortical porosity at the proximal femur, a common site
of the most serious fragility fracture, is associated with
nonvertebral fracture, (ii) the association between porosity
and fracture is independent of aBMD and FRAX, (iii) com-
bining measurements of porosity with aBMD or FRAX im-
proves identification of women with fractures than any one
risk assessment method alone.
Materials and methods
Study design and participants
These hypotheses were tested in the Tromsø Study, a single-
center population-based health study in Norway, which con-
ducted six surveys in 1974, 1979–1980, 1986–1987, 1994–
1995, 2001–2002, and 2007–2008, respectively [21]. During
the Tromsø 4 survey in 1994–1995, all 37,558 eligible inhab-
itants in Tromsø over 24 years were invited and 27,158 sub-
jects (72 %) participated. All their nonvertebral fractures were
registered from the x-ray archives of the University Hospital
of North Norway, Tromsø between Tromsø 4 (1994–1995)
and 1 January 2010 [22, 23].
In a nested case-control design, we identified 1250 women
participating in Tromsø 4, who suffered a fracture at the hip,
wrist, or proximal humerus after the age of 50 years, during
the 15-year registry of fractures (1994–1995 to 2010). We
invited all 760 who still were alive and living in Tromsø. We
recruited 264 fracture cases after excluding premenopausal
women, women with bisphosphonate exposure for osteoporo-
sis, pathological fractures or women with hip prostheses, or
metal screws in the hip region, because metal on one side can
make noise in the CT images of both sides, and therefore
many women with hip fractures could not be included. Age-
matched fracture-free women were randomly selected among
the Tromsø 4 participants, 1186 were invited, and after apply-
ing the same exclusion criteria, 260 controls were recruited.
Of these 524 participants, we excluded 15 currently receiving
hormone replacement therapy and 66 with movement artifacts
during CT scanning. This left 443 women in the final analy-
ses: 232 controls and 211 fracture cases (4 hip, 181 wrist, and
26 proximal humeral). The median time since their index frac-
ture was 6.6 years. All measurements were performed from
November 2011 through January 2013. All participants gave
written informed consent. The study was approved by the
Regional Committee of Research Ethics and the Norwegian
Data Inspectorate and was conducted in accordance with the
World Medical Association Declaration of Helsinki.
Procedures
A self-administered questionnaire included information
concerning all fractures after the age of 50 years, diseases,
use of medication, and lifestyle. Height and weight were
measured in light clothing without shoes. Total hip and FN
aBMD were measured at the nondominant side using DXA
(GE Lunar Prodigy, Lunar Corporation, Madison, WI,
USA), and at the opposite side in those with hip fracture
at the nondominant side, and the coefficients of variation
(CV) were 1.2 and 1.7 %, respectively [24]. The women
were categorized into those with normal FN aBMD,
osteopenia, and osteoporosis using the WHO classification,
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and the T-scorewas based on the National Health and Nutrition
Examination Survey (NHANES III) reference [24].
The 10-year probability of a major osteoporotic fracture
was calculated using the country-specific WHO FRAX algo-
rithm for Norwegian women, including age, height, weight,
parental hip fracture, rheumatoid arthritis, smoking, alcohol
intake, glucocorticoid therapy, and FN aBMD [6–8]. The
nonvertebral fractures used as inclusion criteria of this study
were not included as Bprevious^ fracture in the calculation of
the FRAX score, as the aim was to assess 10-year probability
of fracture before the event, not the probability of fracture after
this event.We did include other fractures that occurred prior to
the index fracture in the FRAX score, and these fractures were
identified from information in questionnaires at the Tromsø 4
and the current study. FRAX is designed to be used with and
without FN aBMD.
CT scans (Siemens Somatom Sensation 16, Erlangen,
Germany) of the nondominant hip were performed at the
Department of Radiology, University Hospital of North
Norway. The CT machine had an in-plane resolution of
0.74 mm, the slice thickness was 0.6 mm, the hip was scanned
from just above the femoral head to 2 cm below the lesser
trochanter (Fig. 1), and the exposure dose of radiation was
~1.5 mSv. Images were analyzed in Melbourne, Australia,
using StrAx1.0 software [25]. As cortices are thin at the prox-
imal femur (femoral head, neck, and trochanter), analyses
were confined to a region of interest (ROI) where the cortices
are thicker. This 3.7-mm subtrochanteric region starts at tip of
the lesser trochanter.
The subtrochanteric region within the ROI in low resolu-
tion CT images was segmented into the compact-appearing
cortex, transitional zones, and trabecular compartment using
StrAx1.0, a non-thresholding method which automatically se-
lects attenuation profile curves as reported using HR-pQCT
images [25]. Porosity within each cortical compartment was
also quantified automatically throughout the ROI, and simi-
larly in CT images as reported in HR-pQCT images [25].
Local bone edges were identified as the beginning and the
end of the rising and falling S-shaped portions of the profile
curve enabling the delineation of the compartments [25].
Compartments were segmented by analyzing ~3600 consecu-
tive overlapping profiles around the perimeter of each cross-
sectional slice. The density profile curve produced had two
plateaus: one corresponding to the compact-appearing cortex
and one corresponding to the trabecular compartment.
Between these plateaus was a descending S-shaped curve or
transition between the two plateaus. This was the transitional
zone. The density profile curve was expressing the mineral-
ized bone area as the percentage of total area within each
column.
Porosity presented in this study is the average void volume
fraction summed using all voxels within the total cortex (com-
pact-appearing cortex, outer and inner transitional zones
(Fig. 1a, b)). The porosity quantified by this algorithm is the
proportion of emptiness within each voxel, or the fraction of
the bone volume occupied by void (porosity). The size and
number of pores were not determined by using this software.
However, it is common practice to be able to accurately quan-
tify structures or objects invisible to the naked eye. To mea-
sure porosity at the subvoxel level, below visibility, two ref-
erent attenuation values are required P: the background (mus-
cle, water etc.) and B: the fully mineralized bone matrix
(1200 mg HA/cm3). The proportion of the voxel volume oc-
cupied by mineralized bone matrix volume is its level of full-
ness (LOF). As previously reported, LOF of each voxel is
estimated as (LOF) %=(Ai-P)/(B-P), where Ai is the attenua-
tion of voxel i [25]. From LOF, the void volume of each voxel
or level of emptiness (porosity)=100–LOF (%) (Fig. 2).
Accuracy of porosity measurements using CT, voxel size
740 microns, was validated ex vivo by testing the agreement
with HR-pQCT measurements, voxel size 82 microns, of the
Fig. 1 a Segmented computed tomography image obtained at the
femoral subtrochanter using non-threshold-based image analysis, show-
ing the total cortical area (the area used for the cortical porosity measure-
ments); consisting of the three cortical compartments: compact appearing
cortex (green), the outer (white), and inner (red) transitional zones, and
trabecular bone area (yellow). b Top left panel shows entire cross section
in a 63-year-old woman (subtrochanteric region) acquired using scanning
electron microscopy. Bottom Left panel shows the same cross section
downsize to simulate a resolution of 740 microns. Top middle panel is
magnified regions of interest (ROI) at 12.5 micron resolution pores are
clearly visible. Bottom middle panel shows the same ROI but downsized
to simulate a resolution of 740 microns. Pores are no longer visible, at
least not as empty pixels. Right panels pores which are clearly visible
have been color-coded green (top panel). Following the downsizing of
the image to simulate a resolution of 740 microns (bottom panel), the
presence of porosity in the image signaled by the green color is clearly
visible although it does not appear as empty pixels
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same ROI at the femoral subtrochanteric region in 5 cadaveric
specimens. The correlation between porosity of the compact
appearing cortex by these methods (R2) was 0.96 (Fig. 3a).
The corresponding R2 were 0.87, 0.87, and 0.94 for porosity
of the outer and inner transitional zones, and the total cortex,
respectively (Fig. 3b–d). As shown in the Bland-Altman plots
(right panels), the error (difference between measurements by
CTand HR-pQCTscanning) ranged from 0 to 10% depending
on the compartment, and agreement between both measure-
ments exceeded 90 %. Validation of the StrAx 1.0 software
analyses of the femoral subtrochanter cortical porosity, as well
as all standard CT parameters in this study, was performed by
repositioning and rescanning a human hip phantom 10 times,
and CVs were between 0.3 and 2.3 %. This human hip phan-
tom was delivered with the CT scanner (Siemens Somatom
Sensation 16, Erlangen, Germany).
Fig. 2 To measure porosity, two
referent attenuation values are
required P: the background
(muscle, water etc.) and B: the
fully mineralized bone matrix
(1200 mg HA/cm3). The
proportion of the voxel volume
occupied by mineralized bone
matrix is its level of fullness
(LOF) and is estimated as (LOF)
%=(Ai-P)/(B-P), where Ai is the
attenuation of voxel i. From LOF,
the void volume of each voxel
or level of emptiness
(porosity)=100–LOF (%)
Fig. 3 Left panels the correlation between CT and gold standard
(HR-pQCT) measurements of porosity of a the compact
appearing cortex, b outer and c inner transitional zones, and d the total
cortex at the femoral subtrochanter (all p<0.05). Right panel Bland-
Altman plots of the error (difference between measurements by CT and
HR-pQCTscanning) ranged from 0 to 10%, and agreement between both
measurements exceeded 90 %
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Statistical analyses
All variables were normally distributed except the FRAX
score. Log-transformation corrected the skewed distribution
and did not change any results. Differences between cases
and controls were assessed using analysis of variance and
adjusted for age. Odds ratios (OR) with 95 % confidence
interval (CI) for fracture were calculated using logistic regres-
sion analyses, adjusted for age, height, weight, FN aBMD,
and FRAX score and expressed per one SD difference and
by threshold levels. To evaluate whether the association be-
tween cortical porosity and fracture was modified by FN
aBMD or FRAX score, we included interaction terms. We
explored sensitivity and specificity for fracture at selected
thresholds for cortical porosity as the 75th, 80th, and 90th
percentile. Using the thresholds for osteoporosis (FN aBMD
T score<−2.5), FRAX score >20 %, and cortical porosity
>80th percentile (based on all participants as reference), as
potential criteria to consider intervention, we calculated the
proportion of women in the fracture and control groups meet-
ing these criteria, and the additional number of women iden-
tified when cortical porosity was included. These data are
presented in Venn diagrams. Analyses were performed using
SAS Software package, v9.3 (SAS Institute Inc., Cary, NC,
USA) and STATA 12.0 (StataCorp, College Station, TX,
USA) with p<0.05 considered significant.
Results
FN aBMD, FRAX, cortical porosity, and fracture
Fracture cases had lower total hip aBMD, lower FN
aBMD, higher FRAX score, and higher femoral
subtrochanteric cortical porosity than controls, all p<0.001
(Table 1). Each SD lower total hip aBMD (OR 2.21; 1.73–
2.83), each SD lower FN aBMD (OR 2.11; 1.66–2.68),
each SD higher FRAX-with-aBMD (OR 2.10; 1.64–2.70),
each SD higher FRAX-without-aBMD (OR 1.62; 1.29–
2.02), and each SD higher cortical porosity (OR 1.71;
1.38–2.11) was associated with fracture (all p<0.001)
(Fig. 4a).
Cortical porosity is associated with fracture independent
of FN aBMD and FRAX
Each SD higher cortical porosity was associated with fracture
independent of total hip aBMD (OR 1.30; 95 % CI 1.02–1.64,
p=0.03) in all women combined. Each SD higher cortical
porosity was also associated with fracture independent of
FN aBMD in all women combined (OR 1.39; 1.11–1.74,
p=0.005, Fig. 4a), in subgroups of women with normal FN
aBMD (OR 1.53; 0.96–2.43), p=0.07, osteopenia (OR 1.32;
1.00–1.75), p=0.055, but not significantly in those with oste-
oporosis (OR 1.46; 0.57–3.71, p=0.43, Fig. 4b).
Similarly, cortical porosity was associated with fracture
independent of FRAX-with-BMD in all women combined
(OR 1.58; 1.27–1.97), p<0.001, in women with normal FN
aBMD (OR 1.88; 1.21–2.94), p=0.005, osteopenia (OR 1.40;
1.06–1.85), p=0.02, but not significantly in women with os-
teoporosis (OR 1.48; 0.68–3.23), p=0.32.
Cortical porosity was also associated with fracture
independent of FRAX-without-BMD (OR 1.73; 1.40–2.15),
p<0.001, Fig. 4a, b. There was no significant interaction
between porosity, aBMD, FRAX-with-BMD, or FRAX-
without-BMD, all p>0.20. Further adjustment for oral corti-
costeroid use did not change the results.
Fracture by porosity >80th percentile,
without or with osteoporosis, or FRAX >20 %
Of all women with fracture, 22 % had normal FN aBMD,
69 % osteopenia, and 9 % osteoporosis (Table 1). Normal
FN aBMD was protective (OR 0.29; 0.19–0.43, p<0.001),
osteopenia was associated with fracture (OR 3.37; 2.16–
5.26, p<0.001), but osteoporosis was not significantly associ-
ated with fracture (OR 1.87; 0.86–4.07, p=0.11). In all wom-
en, independent associations with fracture were observed for
porosity >80th percentile (OR 2.70; 1.63–4.47) and FRAX-
with-BMD >20 % (OR 3.28; 1.77–6.08), both p<0.001.
In the subgroup of women with normal FN aBMD, high
porosity (>80th percentile) was present in 21 % of cases and
4 % of controls and was associated with fracture (OR 6.96;
1.96–24.7, p=0.003). In the subgroup of women with
osteopenia, high porosity was present in 30 % of cases and
19 % of controls and was associated with fracture, but did not
achieve significance at p<0.05 level (OR 1.72; 0.94–3.13,
p=0.08). In the subgroup of women with osteoporosis, high
porosity was present in 39% of cases and 27% of controls but
was not associated with fracture (OR 1.70; 0.33–8.67,
p=0.53).
Additional women with fracture identified by porosity
than FN aBMD or FRAX
Of all 211 fracture cases, only 18women (9%)were identified
using the osteoporosis threshold, 45 women (21 %) using the
FRAX-with-BMD threshold whereas high cortical porosity
level identified 61 women (29 %), Fig. 5. Porosity identified
54 (26 %) women with fractures not identified by the osteo-
porosis threshold and 45 (21 %) women with fractures not
identified by the FRAX-with-BMD threshold. Moreover,
115 (55 %) of fracture cases were not identified by any of
these methods. In addition, FRAX-without-aBMD identified
56 (27 %) women with fractures. When porosity was mea-
sured, 41 (19 %) additional women with fracture were
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identified over that identified by FRAX-without-aBMD alone.
Of 232 controls, osteoporosis was present in 5%, high FRAX-
with-BMD in 7 %, and high cortical porosity in 12 % (Fig. 5).
The sensitivity at these thresholds for osteoporosis, FRAX-
with-BMD, and cortical porosity was 9, 21, and 29 %, and
specificity was 95, 93, and 88 % (Table 2). When porosity
>80th percentile was combined with FRAX-with-BMD
>20 %, the sensitivity for fracture was 43 % and specificity
was 83 %.
Discussion
We report that cortical porosity of the proximal femur was
associated with nonvertebral fractures in postmenopausal
women independent of aBMD and FRAX score. This was
observed in women with normal aBMD and osteopenia, per-
sons commonly regarded as being at low fracture risk.
Porosity was not significantly associated with fracture in
women with osteoporosis. Measurement of porosity identified
26 and 21% additional womenwith fracture than identified by
the osteoporosis or FRAX thresholds, respectively.
Women concerned about bone fragility but found to have
aBMD in the normal and osteopenic range would often be
reassured and not offered therapy even though most fractures
arise from this large segment of the population [4]. The obser-
vations reported here address this unmet need. Measurement
of porosity is likely to improve identification of women
with normal BMD or osteopenia at risk for fracture as
porosity is likely to capture fracture risk not captured by the
aBMD measurement.
This report suggests that proximal femoral cortical porosity
measured from clinical CT images in vivo identifies 26 %
additional fracture cases over that identified by FN aBMD
T-score<−2.5. Several studies demonstrate that measurement
of porosity is associated with fractures and that women with
osteopenia with fractures have higher cortical porosity. Most
of these studies have used HR-pQCT, a method available in
Table 1 Characteristics
in women with fractures
and controls
Cases (n=211) Controls (n=232) p value
Age (years) 68.4 (7.7) 68.3 (6.7) 0.94
Height (cm) 162.7 (6.1) 161.2 (6.6) 0.01
Weight (kg) 68.9 (10.5) 70.0 (10.8) 0.28
Total Hip aBMD (mg/cm2) 854 (113) 930 (115) <0.001
Femoral neck (FN) aBMD (mg/cm2) 794 (100) 860 (112) <0.001
Have normal FN aBMD, n (%) 47 (22.3) 112 (48.3) <0.001
Have osteopenia, n (%) 146 (69.2) 109 (47.0) <0.001
Have osteoporosis, n (%) 18 (8.5) 11 (4.7) 0.11
FRAX score with FN aBMD (%) 15.1 (8.4) 10.8 (4.9) <0.001
FRAX score without FN aBMD (%) 16.3 (10.2) 12.7 (6.2) <0.001
Femoral subtrochanteric parameters
Total bone vBMD (mg HA/cm3) 684 (113) 750 (90.0) <0.001
Cortical vBMD (mg HA/cm3) 1025 (72.6) 1059 (56.6) <0.001
Cortical porosity (%) 43.8 (4.3) 41.7 (3.4) <0.001
Trabecular bone volume/tissue volume (%) 0.27 (0.02) 0.27 (0.02) 0.81
Alcohol intake (drinks/week) 2.7 (2.5) 2.8 (2.3) 0.80
Currently smoking, n (%) 29 (13.7) 24 (10.3) 0.26
Physical activity (h/week) 2.6 (1.6) 2.5 (1.7) 0.42
History of previous fracture, n (%) 54 (25.6) 0
Parental history of hip fracture, n (%) 34 (16.1) 37 (16.0) 0.96
Self-reported excellent/good health status, n (%) 147 (70.3) 165 (71.1) 0.86
Rheumatoid arthritis, n (%) 11 (5.2) 8 (3.5) 0.36
Oral corticosteroid use, n (%) 8 (3.8) 2 (0.9) 0.04
Take calcium supplements, n (%) 44 (20.9) 28 (12.1) 0.01
Take supplements of vitamin D, n (%) 163 (77.3) 166 (71.6) 0.17
Data are mean (SD) or number (%)
p values are adjusted for age using analysis of variance
FRAX Fracture Risk Assessment Tool for calculation of the 10-year probability of a major osteoporotic fracture,
aBMD areal bone mineral density, vBMD volumetric bone mineral density
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only a few centers around the world [18, 20, 26]. We
were unable to show an association between cortical
porosity and fracture in the small group of women with
osteoporosis, due to lack of statistical power. However,
most of the women with osteoporosis at the femoral
neck did not have high porosity. Further studies are needed
to examine this question.
FRAX score was associated with fracture as in other co-
horts [6–8]. However, the measurement of porosity was asso-
ciated with fracture independent of FRAX, and identified
21 % additional women with fracture over that identified by
FRAX-with-BMD threshold >20 %. In settings where bone
densitometry is not available, CT is usually available, and
rather than using FRAX-without-BMD alone, combining this
with porosity assessment appears to identify 19 % more
fracture cases than identified by FRAX-without-BMD
threshold >20 %.
Although measurement of porosity improved sensitivity
for fracture by identifying additional women with fracture
than identified using aBMD threshold for osteoporosis or the
FRAX threshold, 55 % of the fracture cases were not identi-
fied by any of these methods. Thus, improving sensitivity
remains a challenge that may be met by measurement of other
material and structural propertied to build an architectural risk
score and by using fall characteristics. The present results do
not negate the role of trabecular bone in bone fragility. Studies
using HR-pQCT of the distal radius and tibia have reported
trabecular vBMD associated with fracture independent of
aBMD, while one study using CT of the proximal femur re-
ported that only cortical, not trabecular, vBMD remained
Fig. 4 a Odds ratio (OR) and
95 % confidence interval (CI) for
nonvertebral fracture per each
standard deviation (SD) lower in
femoral neck (FN) areal bone
mineral density (aBMD), each SD
higher in fracture risk assessment
tool (FRAX) score with BMD,
each SD higher in FRAX score
without BMD, each SD higher in
cortical porosity, in all women. b
OR (95 % CI) for nonvertebral
fracture per each SD higher
cortical porosity in women with
normal femoral neck areal bone
mineral density (FN aBMD,
n=159, 47 with fracture),
osteopenia (n=255, 146 with
fracture) and osteoporosis
(n=29, 18 with fracture)
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associated with hip fracture after accounting for aBMD
[27–29]. Another study using CT of the proximal femur re-
ported both cortical and trabecular vBMD associated with hip
fractures [30].
In this study, the aBMD using DXA was measured at the
femoral neck, while cortical porosity was measured at the
subtrochanteric region. These two sites are located near each
other, but there are huge differences in site-specific biology as
one site is rich in trabecular bone with a variable thickness of
cortex around its perimeter, the other site consist of a thick
cortex and little trabecular bone. Better understanding of this
site-specific biology may improve the use of cortical porosity
as an indicator of fracture risk for certain individuals.
A strength of this nested case-control study is that it is
based on a general population and a validated fracture registry
[31]. The newly developed StrAx software for quantification
of bone architecture is validated by confirming strong corre-
lation between measurements using CT scans and HR-pQCT,
the method which has been used for previous measurements
of bone architecture, and by rescanning a human hip phantom
using the same standard CT machines as used for the partici-
pants of the study with good reproducibility. The measure-
ments were obtained from the proximal femur, a site of the
most serious and common fragility fracture.
The study has several limitations. The retrospective case-
control design may have introduced selection bias and
the index fractures occurred at a median of 6.6 years before
the women had their CT scans for porosity assessment. As
most of the cases had wrist fractures, we showed that cortical
porosity of the proximal femur is associated with wrist frac-
ture but it remains to study how cortical porosity is associated
hip fracture.
In conclusion, cortical porosity at the proximal femur is a
quantifiable risk factor for fracture that captures additional
elements of bone strength not captured by aBMD or FRAX.
A measurement of porosity improves identification of women
with nonvertebral fracture when combined with aBMD or
FRAX thresholds. Measurement of porosity is likely to better
identify women at increased risk for fractures and to be a
clinically useful tool that helps target treatment to those in
need and avoid unnecessary treatment of those who do not
need it. Further research will be needed to determine the as-
sociation of subtrochanteric cortical porosity with fracture risk
Fig. 5 Venn diagrams illustrate the number and proportion of women
identified using threshold for osteoporosis (femoral neck areal bone
mineral density (BMD) T-score<−2.5), fracture risk assessment tool
(FRAX) score with-BMD >20 %, and cortical porosity >80th
percentile, a in 211 women with fracture and b in 232 controls
Table 2 Sensitivity and specificity for fractures at selected thresholds
Sensitivity % 95 % CI Specificity % 95 % CI
Femoral neck aBMD T-score below −2.5 SD 8.5 5.1–13.1 95.3 91.7–97.6
FRAX-with-aBMD >20 % 21.3 16.0–27.5 93.1 89.0–96.0
FRAX-without-aBMD >20 % 25.1 19.4–31.5 91.8 87.5–95.0
Cortical porosity >75th percentile 33.6 27.3–40.5 83.2 77.7–87.8
Cortical porosity >80th percentile 28.9 22.9–35.5 87.9 83.0–91.8
Cortical porosity >90th percentile 16.1 11.4–21.8 95.3 92.2–97.9
FRAX-with-aBMD or porosity >80th percentile 42.7 35.9–49.6 83.2 77.7–87.8
FRAX-without-aBMD or porosity >80th percentile 44.5 37.7–51.5 80.6 74.9–85.5
FRAX Fracture Risk Assessment Tool for calculation of the 10-year probability of a major osteoporotic fracture, aBMD areal bone mineral density
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in a prospective population study, to improve the sensitivity
using other material and structural abnormalities that contrib-
ute to fracture risk, to determine treatment threshold for corti-
cal porosity and how to best treat those with higher porosity,
as they may need to be treated differently than those individ-
uals with lower aBMD or higher FRAX score.
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